Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category.
Muchtar E, Dispenzieri A, Kumar SK, Ketterling RP, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Gertz MA. Muchtar E, et al. Among authors: zeldenrust s. Leukemia. 2017 Jul;31(7):1562-1569. doi: 10.1038/leu.2016.369. Epub 2016 Dec 1. Leukemia. 2017. PMID: 27904139
Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.
Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, Hayman SR, Buadi FK, Leung N, Zeldenrust SR, Ramirez-Alvarado M, Clark RJ, Kyle RA, Rajkumar SV, Gertz MA. Kumar S, et al. Among authors: zeldenrust sr. Blood. 2010 Dec 9;116(24):5126-9. doi: 10.1182/blood-2010-06-290668. Epub 2010 Aug 26. Blood. 2010. PMID: 20798235 Free PMC article.
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis.
Hwa YL, Gertz MA, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust SR, Leung N, Hayman SR, Gonsalves WI, Kourelis TV, Warsame R, Go RS, Muchtar E, Hobbs MA, Fonder AL, Russell S, Kyle RA, Rajkumar SV, Dispenzieri A. Hwa YL, et al. Among authors: zeldenrust sr. Leukemia. 2019 May;33(5):1268-1272. doi: 10.1038/s41375-019-0400-5. Epub 2019 Feb 8. Leukemia. 2019. PMID: 30737485
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.
Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, Kumar S, Hayman S, Buadi F, Kyle RA, Greipp PR, Lust JA, Russell S, Rajkumar SV, Fonseca R, Dispenzieri A. Bryce AH, et al. Among authors: zeldenrust s. Haematologica. 2009 Mar;94(3):380-6. doi: 10.3324/haematol.13369. Epub 2009 Feb 11. Haematologica. 2009. PMID: 19211640 Free PMC article.
Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type.
Muchtar E, Dispenzieri A, Kumar SK, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Gertz MA. Muchtar E, et al. Among authors: zeldenrust s. Haematologica. 2016 Sep;101(9):1102-9. doi: 10.3324/haematol.2016.147041. Epub 2016 Jun 16. Haematologica. 2016. PMID: 27479823 Free PMC article.
The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment.
Muchtar E, Jevremovic D, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Go RS, Chakraborty R, Zeldenrust S, Kumar SK, Kyle RA, Rajkumar SV, Gertz MA. Muchtar E, et al. Among authors: zeldenrust s. Blood. 2017 Jan 5;129(1):82-87. doi: 10.1182/blood-2016-06-721878. Epub 2016 Oct 11. Blood. 2017. PMID: 27729322 Free article.
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.
Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, Grogan M, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Dispenzieri A. Muchtar E, et al. Among authors: zeldenrust s. Blood. 2017 Apr 13;129(15):2111-2119. doi: 10.1182/blood-2016-11-751628. Epub 2017 Jan 26. Blood. 2017. PMID: 28126928 Free PMC article. Clinical Trial.
Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation.
Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, Gonsalves W, Warsame R, Kourelis TV, Chakraborty R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Dingli D, Leung N, Rajkumar SV, Kyle RA, Kumar SK, Gertz MA. Muchtar E, et al. Among authors: zeldenrust s. Br J Haematol. 2017 Sep;178(6):888-895. doi: 10.1111/bjh.14830. Epub 2017 Jul 12. Br J Haematol. 2017. PMID: 28699650 Free PMC article.
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria.
Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Muchtar E, et al. Among authors: zeldenrust s. Leukemia. 2018 Oct;32(10):2240-2249. doi: 10.1038/s41375-018-0060-x. Epub 2018 Feb 20. Leukemia. 2018. PMID: 29581546
Comparative analysis of staging systems in AL amyloidosis.
Muchtar E, Therneau TM, Larson DR, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Fonder A, Hobbs M, Hwa YL, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A. Muchtar E, et al. Among authors: zeldenrust s. Leukemia. 2019 Mar;33(3):811-814. doi: 10.1038/s41375-018-0370-z. Epub 2019 Jan 23. Leukemia. 2019. PMID: 30675009 No abstract available.
183 results